cronos group glp-1 receptor agonists weight management diabetes treatments Oral GLP-1-Based Therapeutics in the Obesity–Metabolic Syndrome–Diabetes Continuum: Translational Advances, Clinical Barriers, and Emerging Strategies Clinical Management of Weight Regain
Description
- Used an obesity plus osteoarthritis mouse model and showed semaglutide reduced cartilage degeneration, osteophytes, synovial changes, and pain sensitivity

Movement matters: Regular physical activity affects metabolic health in ways supplements cannot replicate

P.O., By mouth

Nat Metab 7 , 12661281 (2025)

The relationship between the bloodbrain-barrier and the central effects of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors
